Aarti Drugs Limited Stock NSE India S.E.

Equities

AARTIDRUGS

INE767A01016

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:46 2024-04-26 am EDT 5-day change 1st Jan Change
504.2 INR +0.79% Intraday chart for Aarti Drugs Limited +1.85% +3.06%
Sales 2024 * 26.12B 313M Sales 2025 * 29.48B 354M Capitalization 46.31B 555M
Net income 2024 * 1.73B 20.75M Net income 2025 * 2.52B 30.16M EV / Sales 2024 * 1.77 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.57 x
P/E ratio 2024 *
26.9 x
P/E ratio 2025 *
18.5 x
Employees 1,003
Yield 2024 *
0.93%
Yield 2025 *
1.35%
Free-Float 36.93%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.79%
1 week+1.85%
Current month+16.08%
1 month+13.75%
3 months-0.08%
6 months+5.42%
Current year+3.06%
More quotes
1 week
491.70
Extreme 491.7
506.60
1 month
431.05
Extreme 431.05
519.15
Current year
431.05
Extreme 431.05
568.00
1 year
418.05
Extreme 418.05
645.75
3 years
313.90
Extreme 313.9
841.80
5 years
105.25
Extreme 105.25
1 026.95
10 years
43.75
Extreme 43.75
1 026.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 76 85-01-04
Director of Finance/CFO 41 12-07-05
Compliance Officer - 19-04-22
Members of the board TitleAgeSince
Chief Executive Officer 76 85-01-04
Director/Board Member 61 87-01-01
Director/Board Member 60 95-09-14
More insiders
Date Price Change Volume
24-04-26 504.2 +0.79% 73,241
24-04-25 500.2 -0.11% 68,793
24-04-24 500.8 +0.18% 76,028
24-04-23 499.8 +1.32% 360,824
24-04-22 493.4 -0.33% 72,115

Delayed Quote NSE India S.E., April 26, 2024 at 07:43 am EDT

More quotes
Aarti Drugs Limited is an India-based company that is engaged in the manufacturing of active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals and formulations. The Company operates through pharmaceuticals segment. The Company's APIs products include ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole and ofloxacin, among others. Its specialty chemicals products include benzene sulphonyl chloride and methyl nicotinate, among others. Its pharma intermediates products include tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, raloxifene and zolpidem. Its products under development include itraconazole, fluconazole, dabigatran, ticagrelor, sitagliptin and alpha lipoic acid. The Company's subsidiaries include Pinnacle Life Science Private Limited, Aarti Speciality Chemicals Limited and Pinnacle Chile SPA.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
503.8 INR
Average target price
562 INR
Spread / Average Target
+11.56%
Consensus

Quarterly revenue - Rate of surprise